

Sophia Zoungas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8460358/publications.pdf>

Version: 2024-02-01

143
papers

12,081
citations

71102

41
h-index

27406

106
g-index

146
all docs

146
docs citations

146
times ranked

14590
citing authors

#	ARTICLE	IF	CITATIONS
1	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 636-646.	2.8	1,446
2	Severe Hypoglycemia and Risks of Vascular Events and Death. <i>New England Journal of Medicine</i> , 2010, 363, 1410-1418.	27.0	1,279
3	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.	6.1	787
4	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	5.2	692
5	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	30.5	542
6	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.	27.0	520
7	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	8.6	462
8	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 431-437.	11.4	379
9	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 2465-2474.	6.3	346
10	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. <i>Diabetes Care</i> , 2014, 37, 2359-2365.	8.6	284
11	Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. <i>Diabetologia</i> , 2012, 55, 636-643.	6.3	262
12	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. <i>Kidney International</i> , 2013, 83, 517-523.	5.2	256
13	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	8.6	230
14	Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1108-1116.	2.8	208
15	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1637-1650.	1.6	205
16	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	5.2	195
17	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020, 98, 839-848.	5.2	193
18	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016, 39, 694-700.	8.6	184

#	ARTICLE	IF	CITATIONS
19	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. <i>Diabetologia</i> , 2021, 64, 275-287.	6.3	140
20	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. <i>Nature Medicine</i> , 2022, 28, 591-598.	30.7	139
21	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 393-398.	2.8	127
22	Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries. <i>Population Health Management</i> , 2019, 22, 127-137.	1.7	120
23	The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. <i>Diabetologia</i> , 2010, 53, 821-831.	6.3	112
24	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	3.9	110
25	Association of Carotid Intima-Medial Thickness and Indices of Arterial Stiffness With Cardiovascular Disease Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 50, 622-630.	1.9	108
26	ARTERIAL STIFFNESS AND CARDIOVASCULAR OUTCOME. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 647-651.	1.9	100
27	Arterial function after successful renal transplantation. <i>Kidney International</i> , 2004, 65, 1882-1889.	5.2	95
28	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 821-832.	11.4	83
29	Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016. <i>Scientific Reports</i> , 2018, 8, 7846.	3.3	80
30	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1796-1803.	8.6	79
31	Hypertension in Reproductive-Aged Women With Polycystic Ovary Syndrome and Association With Obesity. <i>American Journal of Hypertension</i> , 2015, 28, 847-851.	2.0	76
32	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 813-819.	3.6	63
33	Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1891-1897.	8.6	62
34	Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 279-290.	2.3	56
35	The association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney disease. <i>Health Expectations</i> , 2017, 20, 1375-1384.	2.6	51
36	Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 84.	5.3	51

#	ARTICLE	IF	CITATIONS
37	Statins for Primary Prevention in Older Adults—Moving Toward Evidence-Based Decision-Making. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2188-2196.	2.6	50
38	The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 411-421.	4.4	49
39	Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2532.	2.6	48
40	A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. <i>Clinical Endocrinology</i> , 2001, 55, 673-682.	2.4	46
41	A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. <i>Medical Journal of Australia</i> , 2014, 201, 650-653.	1.7	46
42	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged ≥65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 798-805.	3.6	46
43	Association between Heat Exposure and Hospitalization for Diabetes in Brazil during 2000–2015: A Nationwide Case-Crossover Study. <i>Environmental Health Perspectives</i> , 2019, 127, 117005.	6.0	45
44	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	8.6	43
45	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq1 109784314ngBT/O	10.9	41
46	<scp>Sodium-glucose cotransporter 2</scp> inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	4.4	40
47	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. <i>PLoS ONE</i> , 2016, 11, e0146615.	2.5	40
48	Carotid Artery Intima-Medial Thickness Is Increased In Chronic Renal Failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 639-641.	1.9	39
49	The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 126-133.	2.8	39
50	Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 464-469.	4.4	38
51	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e017695.	1.9	38
52	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. <i>Cardiovascular Research</i> , 2019, 115, 266-276.	3.8	38
53	Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. <i>Nephrology</i> , 2004, 9, 130-141.	1.6	37
54	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. <i>Atherosclerosis</i> , 2020, 304, 1-8.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	1.8	35
56	Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. <i>Diabetic Medicine</i> , 2020, 37, 991-999.	2.3	33
57	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0168491.	2.5	33
58	Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World?. <i>Diabetes Care</i> , 2011, 34, 2491-2495.	8.6	32
59	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. <i>Journal of Diabetes</i> , 2018, 10, 699-707.	1.8	32
60	Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 227-235.	2.4	32
61	Obesity, polycystic ovary syndrome and breastfeeding: an observational study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 458-466.	2.8	30
62	Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1967-1975.	8.6	30
63	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 862-872.	4.5	29
64	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 1095-1113.	3.3	28
65	Younger people with Type 2 diabetes have poorer self-care practices compared with older people: results from the Australian National Diabetes Audit. <i>Diabetic Medicine</i> , 2018, 35, 1087-1095.	2.3	27
66	Utilisation of emergency medical services for severe hypoglycaemia: An unrecognised health care burden. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1081-1086.	2.3	25
67	Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). <i>Cardiovascular Diabetology</i> , 2018, 17, 77.	6.8	25
68	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 84-91.	2.8	24
69	Predicting the Effects of Blood Pressure-Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2015, 65, 115-121.	2.7	24
70	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 427-432.	2.3	24
71	A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 265-272.	2.6	24
72	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	6.3	24

#	ARTICLE	IF	CITATIONS
73	Time series modelling to forecast prehospital EMS demand for diabetic emergencies. BMC Health Services Research, 2017, 17, 332.	2.2	23
74	SGLT2 Inhibitors in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 631-633.	4.5	22
75	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. European Heart Journal, 2022, 43, 3243-3254.	2.2	22
76	Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. BMJ Open, 2018, 8, e020677.	1.9	21
77	The association of smoking status with glycemic control, metabolic profile and diabetic complications—Results of the Australian National Diabetes Audit (ANDA). Journal of Diabetes and Its Complications, 2020, 34, 107626.	2.3	21
78	Type 2 Diabetes Patients' Perspectives, Experiences, and Barriers Toward Diabetes-Related Self-Care: A Qualitative Study From Pakistan. Frontiers in Endocrinology, 2020, 11, 534873.	3.5	21
79	Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease. Nephrology Dialysis Transplantation, 2017, 32, gfw383.	0.7	20
80	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	2.8	20
81	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. Systematic Reviews, 2020, 9, 171.	5.3	20
82	Identifying health service barriers in the management of co-morbid diabetes and chronic kidney disease in primary care: a mixed-methods exploration. Family Practice, 2016, 33, 492-497.	1.9	19
83	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 812-821.	4.4	19
84	Effects of a Lifestyle Intervention to Prevent Deterioration in Glycemic Status Among South Asian Women With Recent Gestational Diabetes. JAMA Network Open, 2022, 5, e220773.	5.9	19
85	Primary and tertiary health professionals'™ views on the health-care of patients with co-morbid diabetes and chronic kidney disease — a qualitative study. BMC Nephrology, 2016, 17, 50.	1.8	17
86	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. Cardiovascular Diagnosis and Therapy, 2019, 9, 250-261.	1.7	17
87	Measures of Population Ageing in Australia from 1950 to 2050. Journal of Population Ageing, 2018, 11, 367-385.	1.4	16
88	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care, 2020, 43, 1293-1299.	8.6	15
89	Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neuroscience and Biobehavioral Reviews, 2021, 128, 693-708.	6.1	15
90	Intensification of medication and glycaemic control among patients with type 2 diabetes—The ADVANCE trial. Diabetes, Obesity and Metabolism, 2014, 16, 426-432.	4.4	14

#	ARTICLE	IF	CITATIONS
91	Statins in the elderly. <i>Current Opinion in Cardiology</i> , 2014, 29, 372-380.	1.8	14
92	The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. <i>Internal Medicine Journal</i> , 2017, 47, 461-463.	0.8	14
93	Models of care for co-morbid diabetes and chronic kidney disease. <i>Nephrology</i> , 2018, 23, 711-717.	1.6	14
94	Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. <i>Scientific Reports</i> , 2019, 9, 3256.	3.3	14
95	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 5-11.	4.4	12
96	Mental Health Outcomes in Australian Healthcare and Aged-Care Workers during the Second Year of the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4951.	2.6	12
97	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 527-534.	1.9	11
98	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. <i>PLoS ONE</i> , 2019, 14, e0219685.	2.5	11
99	A lifestyle intervention programme for the prevention of Type 2 diabetes mellitus among South Asian women with gestational diabetes mellitus [LIVING study]: protocol for a randomized trial. <i>Diabetic Medicine</i> , 2019, 36, 243-251.	2.3	11
100	Development, Relative Validity and Reproducibility of the Aus-SDS (Australian Short Dietary Screener) in Adults Aged 70 Years and above. <i>Nutrients</i> , 2020, 12, 1436.	4.1	11
101	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000842.	2.8	11
102	Individual, social and environmental factors and their association with weight in rural-dwelling women. <i>Australian and New Zealand Journal of Public Health</i> , 2017, 41, 158-164.	1.8	10
103	Impact of informed consent content and length on recruitment of older adults into a community based primary prevention trial. <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 89-94.	1.1	10
104	LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 235-238.	4.7	10
105	Effectiveness of management models for facilitating self-management and patient outcomes in adults with diabetes and chronic kidney disease. <i>Systematic Reviews</i> , 2015, 4, 81.	5.3	9
106	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 63-68.	2.3	9
107	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2020, 2020, CD009966.	2.8	9
108	Glycaemia and utilisation of technology across the lifespan of adults with type 1 diabetes: Results of the Australian National Diabetes Audit (ANDA). <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108609.	2.8	9

#	ARTICLE	IF	CITATIONS
109	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2021, 70, 255-261.	0.6	9
110	EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15646.	1.0	9
111	A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease. <i>BMC Nephrology</i> , 2019, 20, 113.	1.8	8
112	The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. <i>Diabetes Care</i> , 2022, 45, 1971-1980.	8.6	8
113	Risk-adjustment of diabetes health outcomes improves the accuracy of performance benchmarking. <i>Scientific Reports</i> , 2018, 8, 10261.	3.3	7
114	Outcomes of people with severe hypoglycaemia requiring prehospital emergency medical services management: a prospective study. <i>Diabetologia</i> , 2019, 62, 1868-1879.	6.3	7
115	Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach. <i>Nutrients</i> , 2019, 11, 1858.	4.1	7
116	Predictors of statin use among older adults: A nationwide cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 156-162.e1.	1.5	7
117	Management of type 2 diabetes in young adults aged 18â€“30 years: ADS/ADEA/APEG consensus statement. <i>Medical Journal of Australia</i> , 2022, 216, 422-429.	1.7	7
118	Evaluating optimal utilisation of technology in type 1 diabetes mellitus from a clinical and health economic perspective: protocol for a systematic review. <i>Systematic Reviews</i> , 2018, 7, 44.	5.3	6
119	Prevalence, incidence and risk factors of diabetes in Australian adults aged â‰¥45Â¥years: A cohort study using linked routinely-collected data. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 22, 100240.	1.4	6
120	Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the <scp>Australian National Diabetes Audit</scp> from 2013 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2603-2613.	4.4	6
121	Utilisation of prehospital emergency medical services for hyperglycaemia: A community-based observational study. <i>PLoS ONE</i> , 2017, 12, e0182413.	2.5	6
122	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 215.	2.4	5
123	Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data. <i>Drugs and Aging</i> , 2020, 37, 393-398.	2.7	5
124	Impact of COVID-19 on Diabetes Health Care and Service Provision in Australian Diabetes Centers. <i>Diabetes Care</i> , 2021, 44, e163-e164.	8.6	5
125	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 467-476.	1.9	5
126	HIGH-SENSITIVITY CARDIAC TROPONIN T FOR THE DETECTION OF MYOCARDIAL INJURY AND RISK STRATIFICATION IN COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145.	2.8	4

#	ARTICLE	IF	CITATIONS
127	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	1.0	4
128	How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients. <i>Nephrology</i> , 2016, 21, 314-320.	1.6	3
129	Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 134.	1.6	3
130	Geographical variation of diabetic emergencies attended by prehospital Emergency Medical Services is associated with measures of ethnicity and socioeconomic status. <i>Scientific Reports</i> , 2018, 8, 5122.	3.3	3
131	Older participant perspectives on permanent study drug discontinuation in an ongoing primary prevention trial of statins. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 841-847.	1.9	3
132	Cardiovascular disease and malignant melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	3
133	Comparing two methods for delivering clinical trial informed consent information to older adults: singular versus stepped approach. <i>Clinical Trials</i> , 2018, 15, 610-615.	1.6	2
134	Exploring HbA1c variation between Australian diabetes centres: The impact of centre-level and patient-level factors. <i>PLoS ONE</i> , 2022, 17, e0263511.	2.5	2
135	Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain. <i>Evidence-Based Medicine</i> , 2017, 22, 219-220.	0.6	1
136	Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1694-1695.	4.5	1
137	Therapy Escalation Following an Elevated HbA1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , 2020, 43, e185-e187.	8.6	1
138	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1472-1481.	0.7	1
139	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
140	Making the most of audit and feedback to improve diabetes care: a qualitative study of the perspectives of Australian Diabetes Centres. <i>BMC Health Services Research</i> , 2022, 22, 255.	2.2	1
141	Microvascular outcomes in type 2 diabetes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 580.	11.4	0
142	Reply to: Statins for Primary Prevention in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 857-858.	2.6	0
143	The authors reply. <i>Kidney International</i> , 2021, 99, 1241.	5.2	0